Link

The impact of statin drugs goes far beyond those declared by the advisory leaflet in the packet. It is really time that the professions got to grips with the fundamental biochemistry of mevalonate inhibitions. More about the book ‘The Dark Side of Statins’ later in the year!

I hope this video will encourage people to consider the wider implications of the biochemical action of statins as they target the important pathway affecting much more than cardiovascular outcomes.

Statin drugs will continue to devastate the quality of life of its users. ‘All cause mortality data’ is not fully released. Failure to appreciate mevalonate pathway effects is allowing this devastating avalanche of adverse impacts to continue, with the blessing of professionals who should know better.

Statins – The Dark Side – Video Link

Primary prevention with a statin increases mortality.

Unless you have already had an MI, say “no, thank-you” to the recommends statin therapy. Statins lead to cognitive impairment, memory loss, mental confusion, depression, dementia, diabetes, neuropathy, parasthesia and neuralgia, and appeared to be at higher risk to the debilitating neurological diseases, ALS and Parkinson’s disease.
The statin industry has enjoyed a thirty year run of steadily cooking the data.
TREAT HEART DISEASE: Spend significant time outdoors; evidence of the benefits of sun exposure to the heart is compelling,……..
eat healthy, cholesterol with animal-based foods like eggs, eat fermented foods like yogurt and sour cream; eat foods rich in sulfur like onions and garlic

James J. King September 22, 2012 12:19 (EDT) see comment #1

Quote

Statins for all? (BMJ Extract)
An epidemiologist’s call for all healthy adults over 50 to take statins was uncritically reinforced by the media without proper discussion of side effects. A problem for primary care doctors is that even rare side effects become common when millions of low risk patients are treated with statins……………………….As for evidence that high risk patients are deciding not to take statins because of a perceived risk of side e‹ ects, this seems to be based on anecdote, and my own anecdote is also that many patients decline to take statins, saying that the side effects are unacceptable.
The arguments for giving statins to a whole population need to be made equally in forms of absolute risk; we must be fair about potential side effects, including the association with diabetes; and crucially we must also be clear that improving population health should not simply
be made the work of drug companies.

Margaret McCartney general practitioner, Glasgow
References are in the version on bmj.com.
BMJ 2012;345:e6044